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Abstract Immune activation is a regular feature of sepsis, but
the incidence and nature of the ensuing inflammation-
resolving and immunosuppressive component is less well
understood. In this study, we compared immunoregulatory
markers on blood leukocytes from patients with Gram-
negative or Gram-positive sepsis or septic shock, and com-
pared this to blood from patients with severe virosis or healthy
controls. To this end, blood from 32 patients with sepsis,
including ten cases with shock, and 12 patients with severe
virosis were analysed by flow cytometry for the expression
levels of monocyte HLA-DR, CD11c, CD14 and CD40, and
for frequencies of CD163+-suppressive monocytes, HLA-
DR+ or CD40+-activated T cells and Tregs. Plasma cytokine
levels were analysed as a functional measurement. Signs of
immunosuppression dominated in the septic shock and Gram-
positive sepsis groups, whereas monocyte activation was
common in Gram-negative sepsis patients without shock.
However, the main finding was the large inter-individual
variation of immune activation and immunosuppression, with
no correlation to prognosis among the shock patients. The
pronounced inter-individual variation in the analysed mono-
cyte and lymphocyte markers forms a strong argument that,
when immunomodulatory treatment is considered in a sepsis








MFI Mean fluorescence intensity
PD-1 Programmed cell death protein 1
PE Phycoerythrin
PE-Cy7 PE-cyanine7
PRRs Pattern recognition receptors
SIRS Systemic inflammatory response syndrome
Tregs T regulatory cells
Introduction
The incidence of sepsis is increasing, and there is still a high
mortality associated with severe sepsis [1–4]. A wide spec-
trum of host responses [4–6] contribute to the considerable
clinical heterogeneity, as well as to the repeated failures of
clinical trials with inflammatory modulators [7–9]. The pres-
ence of a prominent immune activation, with a “cytokine
storm”, and even a “genomic storm” as shown in response
to low-dose bacterial endotoxin [10], can be a sine qua non
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sepsis factor, occurring early and acting anti-microbially for
the benefit of the host. Recently, consequences of the admin-
istration of immunosuppressive therapy became the subject of
much attention [11–14]. Nowadays, these approaches are
considered to be a major cause of sepsis mortality.
It is a debated question whether or not signs suggesting
immunosuppression can be viewed to form a state of com-
pensatory anti-inflammatory response syndrome (CARS) or
not [8, 9, 11, 14]. A perplexing sign observed early and in
most sepsis patients is lymphopenia, mediated at least in part
by apoptosis [15]. Whether this lymphopenia should be
regarded as part of a compensatory immunosuppression, thus
contributing to organ dysfunction and opportunistic infections
commonly seen in later stages of the disease, is unknown.
Experimental studies performed in mice suggest that inhibi-
tion of the sepsis-induced lymphocyte apoptosis specifically
increases survival [16]. It has also been shown that T lympho-
cytes repopulate their respective compartments after sepsis via
tightly regulated mechanisms [17]. Neither is it known wheth-
er clinically significant immunosuppression is a common
phenomenon, or only occurring in the most advanced patients,
thus rarely indicating a need for immune-restoring therapy.
The answers to such questions are important because they
decide whether sepsis patients should be monitored with
immune biomarkers, and whether there is a need to develop
appropriate immunomodulating therapeutics.
In this study, we made an attempt to broadly document the
incidence and nature of immune alterations in sepsis patients
with different clinical severity and causative microorganisms
(19 gram-negative and 13 gram-positive patients) and com-
pared this to patients with generalised virosis or healthy con-
trols. We report that a marked inter-individual variation among
sepsis patients indicates that sepsis care may benefit from a




Samples from all of the sepsis and virosis patients were
obtained within 4 days after admission to hospital. The ma-
jority of samples were taken within 2 days [Gram-positive
sepsis patients (7/10) and Gram-negative sepsis patients (7/
12)] and those taken later than 2 days were especially con-
trolled to not bias the conclusions in our study. For shock
patients, the samples were obtained within 2 days. All patients
were prospectively included, to cover a spectrum of illness
severity including shock, and to have several microbial caus-
ative agents represented. Swedish national guideline criteria
for sepsis diagnosis were adhered to, being similar to those of
Bone et al. [18]. Sepsis was, thus, defined as the presence of a
suspected or microbiologically proven infection, together with
a systemic inflammatory response syndrome (SIRS), with
SIRS defined by at least two of the following parameters:
hypothermia (≤36 °C) or hyperthermia (≥38 °C); tachycardia
(≥90/min); tachypnoea (≥20 breaths/min) and/or arterial
PCO2 32 mmHg or lower and/or mechanical ventilation; and
leukocytosis (≥12,000/μl) or leukopaenia (≤4,000/μl) and/or a
left-shifted white blood cell differential count of 10 % or
higher. Septic shock was defined as sepsis-induced hypoten-
sion persisting despite adequate fluid administration. There
were 19 patients with sepsis, three patients with severe sepsis
and ten patients with septic shock (Table 1). Since the patients
with severe sepsis were so few, we chose to define them in the
group of sepsis but not septic shock. Standardised antibiotic
treatment according to Malmö University Hospital’s guide-
lines was given until the cultures were finalised. The follow-
ing subjects, with the indicated microbial agents recovered by
culture or diagnosed by polymerase chain reaction (PCR)
(using Swedish national QC-approved methods) were includ-
ed: septic shock (n =10, 3 females and 7 males), with blood
culture isolate of Escherichia coli (4 patients), Klebsiella
oxytoca (1 patient), Staphylococcus aureus (2 patients),
Streptococcus pyogenes (1 patient), and in two patients, no
microbiological agent was isolated from blood but with
suspected Gram-positive (1 patient) and Gram-negative (1
patient) etiology (these patients responded quickly to either
Gram-positive or Gram-negative antibiotic treatment and also
had clear symptoms from either the urinary tract or the lungs);
Gram-positive sepsis (n =10, 3 females and 7 males), with
blood culture isolate of S . aureus (3 patients), S . pneumoniae
(4 patients), anaerobic cocci (1 patient) and the 9th and 10th
patients with a probable pneumococcus etiology; Gram-
negative sepsis (n =12, 8 females and 4 males), with blood
culture isolate of E . coli (3 patients), K . oxytoca (1 patient),
Citrobacter koseri (1 patient) and another five patients with
significant quantity of E . coli in urine (Table 1). The virosis
cases (n =11, 8 females and 3 males) were one influenza A,
four influenza B, two influenza H1N1 (one coinfected with
influenza A), one hepatitis A, one acute hepatitis B and two
HSV2 patients. Healthy controls were also included (n =13, 9
females and 4 males). Ethical permit was obtained from the
local ethical committee at Lund University (Dnr 288/2007)
and an informed consent was given from the participating
patients or their relatives if the patient was not in a condition
to provide an informed consent him/herself.
Blood clinical routine methods
Venous blood was drawn in EDTA tubes and the time between
sample collection and analysis was less than 6 h. The leuko-
cyte concentration and differential count were determined
using an LH750 machine (Beckman Coulter, Hialeah, FL,
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USA) using Swedish national QC-approved clinical diagnos-
tic methodology.
PCR method for Tregs
The analysis of FOXP3+ T regulatory cells (Tregs) was
performed byDNAmethylation of the FOXP3 CpG-rich gene
promoter, as previously described [19]. A limited number of
whole blood samples was available for this purpose.
Flow cytometry
In this study, we chose to use the following markers; CD3, a
marker for all T cells; CD8, a marker for cytotoxic T cells;
CD11c, expressed on and used as a marker for dendritic cells,
monocytes, macrophages, neutrophils and some B cells;
CD14, expressed on all monocytes; CD40, the receptor for
T cell-CD40L expressed on antigen-presenting cells (APCs)
and indicates the level of activation, but is also expressed on a
small subpopulation of CD3+ T cells [20]; CD163, a scaven-
ger receptor expressed on monocytes and macrophages and
often used to represent activated anti-inflammatory cells [21];
HLA-DR, the human major histocompatibility complex class
II used as an activation marker on monocytes, but also as a
marker of immune suppression when downregulated. HLA-
DR can be expressed in activated Tcells during severe infections
[22].
The stainings were performed in a routine flow cytometry
laboratory at Skåne University Hospital Malmö, with internal
controls for isotype or staining variations. Whole blood
Table 1 Clinical characteristics









Age, median years (range) 74 (51–87) 68.5 (33–89) 51 (20–79) 46 (26–64)
Males 7 7 4 4
28-day mortality 3 1
Length of ICU stay
Days median (range) 6 (1–49) 0 0 n/a
Length of hospitalization
Days median (range) 23 (3–53) 7 (3–55) 4 (3–46) n/a
Ventilation
Days median (range) 6 (0–49) 0 0 n/a
Nosocomial infection
Percentage (number) 50 (n =5) 0 0 n/a
WBC count at enrollment
Cells (×106)/ml median (range) 20 (1.5–60.4) 18 (8.6–32.3) 8.7 (5.1–32.4) 5.7 (4.6–11)
Lymphocyte count at enrollment
Cells (×106)/ml median (range) 1 (0.1–2.4) 1 (0.3–2.1) 1.2 (0.5–2.4) 1.8 (0.8–3.7)
Comorbidities
Diabetes 3 3 3 n/a
Renal failure 1 1 0 n/a
Cardiovascular disease 5 6 4 n/a
Pulmonary disease 6 3 0 n/a
Metastatic cancer 1 0 1 n/a
Blood or urine culture finding
Escherichia coli 4 n/a 10 n/a
Citrobacter koseri 0 n/a 1 n/a
Staphylococcus aureus (1 TSSS+) 2 3 n/a n/a
Streptococcus pyogenes 1 0 n/a n/a
Klebsiella oxytoca 1 n/a 0 n/a
Klebsiella pneumoniae 0 n/a 1 n/a
Streptococcus pneumoniae 0 4 n/a n/a
Gram-positive anaerobic cocci 0 1 n/a n/a
No bacteria isolated from blood/urine 2 2 0 n/a
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(50 μl) in each of the four tubes was incubated at room
temperature with antibodies conjugated with the fluoro-
chromes fluorescein isothiocyanate (FITC), phycoerythrin
(PE), PE-Texas Red, allophycocyanin (APC) or Alexa-Fluor
647 and PE-cyanine7 (PE-Cy7) to permit up to five-colour
analysis. The following antibodies were used: negative con-
trols IgG1-PE or -FITC (clone 679.1Mc7; Beckman Coulter),
CD45-ECD (clone J33; Beckman Coulter), CD3-APC, -PE,
-ECD or -PCy5 (clone UCHT1; DakoCytomation), HLA-DR-
FITC (clone L243; Becton Dickinson), CD8-ECD (clone
SFCI21Thy2D3; Beckman Coulter), CD14-PE-Cy7 (clone
RM052; Beckman Coulter), CD40-PE (clone MAB89;
Immunotech Beckman Coulter), CD64-FITC (clone 22;
Immunotech Beckman Coulter), CD11c-PE (clone BU15;
Beckman Coulter). The combination of antibodies used were
as follows for each tube: negative control-FITC/negative
control-PE/CD45-PE-Texas Red/CD3-APC, HLA-DR-
FITC/CD3-PE/CD8-PE-Texas Red/cholera toxin B-Alexa
Fluor 647/CD14-PE-Cy7, HLA-DR-FITC/CD40-PE/CD3-
PE-Texas Red/cholera toxin B-Alexa Fluor 647/CD14-PE-
Cy7, CD64-FITC/CD11c-PE/CD45-PE-Texas Red/cholera
toxin B-Alexa Fluor 647/CD14-PE-Cy7. The results for chol-
era toxin B and CD64 were scored only as part of a separate
granulocyte study. Background autofluorescence and non-
specific binding of mouse Ig were monitored for two of the
colours (FITC and PE) with isotypic non-specific mouse Ig,
separately for lymphocytes and monocytes; the FITC-labelled
non-specific mouse IgG was also used for setting the cut-off
for HLA-DR-positive reaction in T cells. Monocytes were
defined as CD3−CD14+ cells with light-scattering typical for
monocytes (when HLA-DR and CD40 were scored) or as
CD14+ cells with CD45 intensity and light-scattering typical
for monocytes (when CD11c was scored). The technical var-
iation is low, as illustrated by the small variation observed for
ten separate determinations of monocyte and lymphocyte
HLA-DR (ten 50-μl blood fractions from one patient were
labelled with anti-HLA-DR-FITC; data not shown). A lyse-
no-wash protocol, or the automated Beckman Coulter TQprep
machine, was used. In-house solutions for lysis and fixation
were used. At least 1,000 events were analysed in an FC500
Beckman Coulter flow cytometer using both lasers. Acquisi-
tion and analysis were made using the CXP software
(Beckman Coulter). Flow cytometry analysis of monocyte
CD163 was performed as part of a separate study, on a
subgroup of the shock patients (n =6; four with Gram-
positive and two with Gram-negative septic shock), using a
FACSCalibur and the antibody conjugates CD14-FITC (clone
M5E2), CD163-PE (cloneGHI/61) and HLA-DR-APC (clone
G46-6) from Becton Dickinson. An immune response index,
intended to function as an indicator of overall immuno-
activation or immunosuppression, was calculated for each
patient. This index is based simply on those immune status
parameters used in this study. It is, therefore, based on the
results for three-monocyte (expression of HLA-DR, CD11c
and CD40) and two-lymphocyte (frequency of activated
CD3+ and CD8+ T cells) parameters. One point is awarded
for a variation of one standard deviation from the mean of the
healthy control result, up to a maximum of three standard
deviations per parameter; for example, −0.8 SD for HLA-
DR, −0.7 SD for CD11c, +3.1 SD for CD40, +5.6 SD for
CD3+ T and +6.5 SD for CD8+ T give an index of +1.5,
indicating overall immunoactivation.
Cytokine analysis
Plasma was fresh-frozen at −20 °C and then analysed for IL-6,
IL-1β, IL-18, TNF-α and TIMP-1 by enzyme-linked
immunosorbent assay (ELISA). The minimum detectable
concentrations were: IL-6 0.70 pg/ml, IL-1β 10 pg/ml,
IL-18 12.5 pg/ml, TNF-α 10 pg/ml and TIMP-1 0.08 ng/ml.
All ELISA kits were from R&D Systems.
Statistical analysis
The non-parametric Wilcoxon’s two-sample rank test (the
Mann–Whitney test) was used, and a p -value <0.05 was
regarded as significant. Pearson’s correlation coefficient was
calculated in order to measure the correlation (linear depen-
dence) between two variables. The calculation of the immune
response index was based on the standard deviation because
the healthy control data were considered to reflect a normal
distribution.
Results
Markers of monocyte activation
Peripheral blood obtained from sepsis and virosis patients was
analysed for leukocyte surface markers by flow cytometry. The
results for the relative antigen density of four proteins (HLA-
DR, CD11c, CD40 and CD14) known to be expressed by
virtually all monocyte subsets, and with their level of density
reflecting cellular activation status, are presented in Fig. 1a.
This was performed as an attempt to illustrate the systemic
innate immune response in these patients. The result is given
as the mean fluorescence intensity (MFI), with the healthy
controls’ (n =13) mean value set to 1.0. The shock group
consisted of both Gram-negative and Gram-positive cases,
but was kept as one group because of the homogeneous pattern
seen among the shock patients. Amajority of the shock patients
(9 out of 10 cases) (p <0.001) and of the patients with Gram-
positive sepsis (7 out of 10) (p <0.01) had a reduced MFI level
of HLA-DR (i.e. an MFI lower than all of the healthy controls),
whereas this was seen with only one case of Gram-negative
sepsis (1 out of 12) and one case with virosis (1 out of 11).
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Monocyte HLA-DR was significantly lower in septic shock as
compared with Gram-negative sepsis (p <0.001). It has been
proposed that HLA-DR−/low monocytes are anti-inflammatory
cells that have been reprogrammed from conventional HLA-
DR+ monocytes to elicit immunosuppressive signals [23]. In
septic shock patients (p <0.001) and in patients with Gram-
positive sepsis (p <0.01), the size (%) of the HLA-DR−/low
monocyte population was increased, while patients with
Gram-negative sepsis and virosis had normal proportions of
HLA-DR−/low monocytes (Fig. 1b).
For CD11c, there was a reduction in MFI levels on mono-
cytes in patients with shock and Gram-positive sepsis as
compared to healthy controls (p <0.001 and p <0.05, respec-
tively). Noticeably, in the Gram-negative sepsis group, strong-
ly CD11c++ monocytes were found in 8 of the 12 studied
patients as compared to healthy controls (p <0.001). Many
cases from the virosis group also had a relatively high CD11c
expression (Fig. 1a).
CD40 MFI levels varied in the septic shock group, where
equally as many shock patients had monocytes with increased
or decreased (4 out of 10 and 3 out of 10, respectively) levels
of CD40 expression. The Gram-positive sepsis patients also
showed a large variation in CD40 expression with increased
or decreased levels of CD40 expression (2 out of 10), while a
majority of Gram-negative sepsis patients (p <0.001)
presented with an increased level of CD40 (Fig. 1a).
The CD14MFI levels were significantly reduced onmono-
cytes in patients with shock and Gram-positive sepsis (p <
0.001). Most of the Gram-negative sepsis patients and virosis
patients had CD14 expression within the normal range
(Fig. 1a).
CD163+ monocytes increase in sepsis
The fraction of monocytes with high expression of CD163, a











































































































































































Fig. 1 Immunophenotyping of monocytes. a Peripheral blood was
analysed by flow cytometry. The results show the mean fluorescence
intensity (MFI) of the indicated markers expressed on monocytes. The
thick black lines represent the mean for each group. Healthy controls
(HC). p-values for the sepsis groups are shown. *p <0.05, **p<0.01,
***p <0.001. b Size of the anti-inflammatory HLA-DR−/low monocyte
population in peripheral blood (% of gated monocytes). *p <0.05, **p <
0.01, ***p<0.001. Shock patients (n =10), Gram-positive sepsis patients
(n =10), Gram-negative sepsis patients (n=12), virosis patients (n =11)
and HC (n =13)
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elevated in all the analysed shock cases (with 6–88 %
CD163++ monocytes of all CD14+ gated monocytes, as com-
pared with 0–1 % CD163++ monocytes in the healthy con-
trols) (Fig. 2; p <0.001), indicating that the observed reduction
of monocyte HLA-DR, CD11c and CD14 during shock is not
merely a reflection of low vitality and general downregulation
of monocyte protein levels.
Marker (HLA-DR) of T lymphocyte activation
As an attempt to illustrate the systemic adaptive immune re-
sponse in septic patients, we next analysed the activation status
of Tcells usingHLA-DR or CD40 expression, and the presence
of Tregs (Fig. 3). The reason for the somewhat controversial
choice of T cell activation markers was in an attempt to extract
as much data as possible from already performed monocyte
activation analyses. Although T lymphocyte HLA-DR, being
anMHC class II molecule, does not directly participate in Tcell
activation, and seems not to be expressed in most T cells, its
presence on the Tcell surface is known to become detectable in
response to virus infection. Moreover, we recently reported that
the fraction of T cells with HLA-DR is typically increased for
both the CD4+ T helper and CD8+ T cytotoxic subsets during
various acute infections [22]. As expected, most virosis cases
showed an increased proportion of HLA-DR+ cells within the
studied Tcell populations (p <0.05 for HLA-DR+ CD3+ Tcells
and p <0.05 for the HLA-DR+ CD3+ CD8+T cells). Interest-
ingly, four out of ten shock patients had a markedly increased
proportion of HLA-DR+ CD3+ Tcells, while one had a reduced
population (Fig. 3a). These same four cases also had an in-
creased HLA-DR-positive fraction among the CD8+ T cell
subgroup, while three out of ten of the shock cases had a clearly
reduced fraction of HLA-DR+ CD8+ T cells. In Gram-negative
sepsis, there were several patients with a slightly increased
fraction of HLA-DR+ CD3+ T cells (5 out of 12), but, also, a
decrease was seen in 7 out of 12 patients for both HLA-DR+
CD3+ T cells and HLA-DR+ CD8+ T cells. In Gram-positive
sepsis, there were several patients with an increased fraction of
HLA-DR+ CD3+ T cells (4 out of 10), but also a decrease was
seen in two out of ten patients for both HLA-DR+ CD3+ Tcells
and HLA-DR+ CD8+ Tcells. Overall, the Gram-positive sepsis
cases showed a large inter-individual variation. There was no
statistically significant difference between any of the sepsis
groups and the healthy controls, because of the large inter-
individual variation among the patients (Fig. 3a).
CD40 is a co-receptor normally expressed on APCs. CD40
interacts with CD40L expressed on T cells and its expression
is increased upon activation, leading to an increased T cell
activation (CD40:CD40L interaction). Interestingly, also, a
small population of T cells can express CD40 upon activation
[16, 20]. We, therefore, evaluated next whether CD40 expres-
sion on CD3+ T cells would increase upon sepsis or septic
shock. As shown in Fig. 3b, the subpopulation of CD40+
CD3+ T cells increased significantly in all patient subgroups
with bacterial infections as compared to healthy controls, but
not in virosis patients.
Tregs is a specific T cell subtype with immunosuppressive
function. By analysing cytosine methylation of the CpG-rich
FOXP3 gene promoter (demethylation of this region is highly
specific for Tregs, see [19]), we found a marked variation in
Treg number in the six analysed shock patients, ranging from



































































 Monocyte CD163  subset with suppressive function++Fig. 2 Frequency of a monocyte
CD163+ cell type with
immunosuppressive function.
The fraction of monocytes with
high CD163 expression
(CD163++) was determined by
flow cytometry using peripheral
blood from six patients with
septic shock and ten healthy
controls. The dot plots are gated
on CD14+ monocytes (for the
gates, see the left dot plots). The
demographics did not differ
significantly compared with all
the patients with septic shock
(according to mean age and sex
ratio). The right dot plots (CD163
vs. HLA-DR) show a variable
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analysed healthy controls up to three times that of the highest
of the controls (Fig. 3c). For Gram-positive sepsis (four pa-
tients were analysed), there was a lowered or normal Treg
level; in contrast, patients with Gram-negative sepsis
displayed an increased level, for all three cases analysed by
PCR. In the virosis control group, there were only slight
deviations from the normal Treg frequency (analysed with
the DNA methylation method; results not shown).
Immunoreactivity patterns of individual patients
As mentioned above, CD40 is known to enhance T cell
activation (CD40:CD40L interaction). To be able to determine
whether strong monocyte expression of CD40 is accompanied
by a high fraction of HLA-DR-positive T cells, we analysed
the individual patterns of relative monocyte CD40 MFI as
compared to the proportion of HLA-DR+ CD3+ CD8+ T cells
(Fig. 4a). There was no apparent correlation between mono-
cyte CD40 expression and the frequency of HLA-DR+ CD3+
CD8+ Tcells (or activated HLA-DR+ CD3+ Tcells; results not
shown) in single individuals. The CD40 MFIhigh sepsis pa-
tients (four with septic shock, nine with Gram-negative sepsis
and two with Gram-positive sepsis) differed widely in the
result for activated T cells, although the Gram-negative sepsis
patient group showed a trend towards high monocyte CD40
MFI with few activated T cells.
The heterogeneity among the sepsis patients was high. The


































































































































































   
   
   
   
   
   
   






























  FOXP3+              
(PCR method)            
Fig. 3 Immunophenotyping of lymphocytes. a Peripheral blood was
analysed by flow cytometry. The results show the fraction of all T cells
with cell surface HLA-DR, and the result for healthy controls is set to 1.0.
Healthy controls (HC). p-values for virosis and shock are shown (p<
0.05), and refer to a comparison with the healthy controls. The thick black
lines represent the mean for each group. b The fraction of CD40-ex-
pressing CD3+ T cells was analysed. The values shown in the graph are
the ratio of CD40+ CD3+ T cells (%)/CD40− CD3+ T cells (%) for each
patient. HC healthy controls. *p <0.05, **p<0.01, ***p<0.001. Shock
patients (n =10), Gram-positive sepsis patients (n =10), Gram-negative
sepsis patients (n=12), virosis patients (n =11) and HC (n =13). c The
frequency of Tregs was analysed by PCR analysis of DNAmethylation of
the FOXP3 gene promoter. Blood was from patients with septic shock
(n =6), Gram-positive sepsis without shock (n =4), Gram-negative sepsis
without shock (n =3) and HC (n =4 for PCR)
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shown in Fig. 4b. Importantly, an immunosuppressive pattern
was never consistently found in any of the patient subgroups,
but, rather, the opposite with mixed phenotypes within one
patient and subgroup. Examples shown are one Gram-
negative shock patient (subject A) displaying a dichotomy
between the monocyte and lymphocyte immune responses
and one Gram-positive shock patient (subject B) displaying
an increased monocyte and lymphocyte immune activity, with
a concurrent decreased HLA-DR and CD11c expression. Only
seven of the 32 sepsis patients showed either a homogeneous
pattern of either immunosuppression or immune activation.
In an attempt to provide an indicator of the net immune
response for each patient, the results for three monocyte and
two T cell parameters were used to calculate an immune
response index (see “Materials and methods”). For the shock
and the Gram-positive sepsis groups, the majority of the
subjects shows an index suggesting a relatively normal index
as compared to healthy controls, whereas all of the Gram-
negative patients display a positive index indicating immuno-
activation (Fig. 5). Also among the non-surviving shock indi-
viduals, there is variation: two cases with a positive index and
two cases with a negative index. Negative values suggesting
immunosuppression were seen for samples taken before day 1
as well as after 4 days, indicating no correlation with sepsis
duration. No gender differences in any of the cell surface
markers were detected.
Cytokines
A majority of the patients and all of the healthy controls were
analysed for plasma cytokine levels. Plasma IL-6 is produced
mainly by activated monocytes/macrophages and considered
to be a pro-inflammatory cytokine. Anti-inflammatory effects
of this cytokine have also been proposed [20]. Significantly
elevated levels (p <0.05) of plasma IL-6 was seen in patients
with septic shock and in the Gram-positive sepsis group as
compared to healthy controls (Fig. 6). One healthy control had
high levels of IL-6, with otherwise normal values of all
other analysed markers, but the reason for this is un-
known. A markedly elevated level of IL-18 was seen in the
Gram-positive sepsis group as compared to healthy controls
(p <0.01), but only to a moderate extent in the shock group.
TIMP-1 is a metalloproteinase inhibitor produced by many
cell types in response to IL-6 and other macrophage cytokines,
with diverse functions possibly including those important for
the resolution of inflammation [24]. TIMP-1 was analysed
instead of IL-10 due to previous experiences with large vari-
ations using IL-10. Subjects with an elevated level of TIMP-1
were mainly found in the Gram-negative sepsis and septic
shock group (p <0.001) (Fig. 6). High levels of IL-1β and
TNF alpha were seen in a few healthy controls as well as
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Fig. 4 a Monocyte CD40 expression in relation to activated CD8+ T
cells. The results showmonocyte CD40 intensity (MFI) and fraction of T
cells being positive for HLA-DR. The CD40 expression level for healthy
controls is set to 1.0. Each symbol denotes the result of one patient.
Healthy controls (HC). Shock patients (n =10), Gram-positive sepsis
patients (n =10), Gram-negative sepsis patients (n=12), virosis patients
(n =11) and HC (n=13). b Variation in immune response pattern between
individual patients. The monocyte and lymphocyte results for two pa-
tients are shown, with each panel representing one subject. The dotted
line is the mean of the healthy controls. HLA-DR, CD11c and CD40
showmonocyte expression level; CD3+ HLADR+ indicates the frequency
of activated CD3+ T cells; CD8+ HLADR+ indicates the frequency of
activated CD8+ T cells
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Discussion
Sepsis is considered to be a complex disorder, and it has been
suggested that it is probably too heterogeneous to treat as one
disease [4]. One obvious reason is the variety of eliciting
microbial agents carrying distinct sets of pathogenic factors.
Many host factors influence the clinical picture, such as ge-
netic determinants and co-morbidities influencing immune
status. There can be variation even within the individual
patient, as exemplified by an early appearing SIRS eliciting
CARS [4, 11, 25]. Even though viruses are not conventionally
judged to cause sepsis, we decided to use virosis as the control
subgroup due to the systemic effects elicited by the immune
response in these patients.
Monocyte cytokine production and the expression of sur-
face markers are well known to become depressed in many
sepsis patients [4–6, 11–13, 26, 27]. For instance, a weak
production of pro-inflammatory cytokines by ex vivo-stimu-
lated monocytes and a low level of cell surface CD14 expres-
sion were noted to correlate with sepsis severity [28]. How-
ever, a more recent report also demonstrated a high level of
immunosuppressive CD163+ monocytes already upon admis-
sion, and with no difference 7 days later, and with a lack of
correlation between the frequency of this monocyte subset and
clinical outcome, illustrating the complexity of the immune
response in sepsis [29].
There was a wide variation in age between the study
groups, with the oldest patients found in the group of septic
shock. There is clear evidence that the incidence of sepsis
increases slowly throughout most of adulthood, and the rea-
sons for this is multifactoral [30]. It is generally agreed that the
senescence in the immune system affects the adaptive immune
response, which leads to major defects in the cell-mediated
immunity and the humoral immune response, whereas the
innate immune response is largely spared during life [31]. In
this study, there were more males than females developing
septic shock. It has been reported that the gender-related
differences in the immune response could be part of the
explanation for this behaviour [32]. A predominance of anti-
inflammatory mediators in women may have a protective
effect in terms of developing severe sepsis and septic shock
[32].
Most of our patients had one or several abnormal findings
among monocytes and/or T lymphocytes deviating strongly
from that of all the 13 healthy controls. Signs of immunosup-
pression were most evident in septic shock, regarding both the
number of patients and the size of the alteration. However, this
was sporadically seen also in all the other diagnostic groups
studied, including the non-septical virosis group. Indeed, it
should be noted that the levels of antigen cell surface expres-
sion are overlapping in a lot of cases. Therefore, conclusions
regarding the immune status are impossible to draw. Still, we
believe that our data indicate that the suppression of some
immune functions most probably occurs in a majority of
patients with sepsis, as well as in other severe infections.
However, our main finding is the marked inter-individual
variation regarding the number and intensity of signs of im-
munoreactivity. A major former study on immune changes
during acute sepsis in humans suffers from a bias in terms of
the fact that only samples from deceased patients were
analysed [12]. The present study does not have that bias and
suggests that, at least for the limited panel of markers used
here, large inter-individual differences are evident. We em-
phasise the complexity of the homeostatic network operating
in a sepsis patient that eventually decides whether or not the
net result will be a functional clinically overt immunodefi-
ciency [33, 34]. These considerations are in line with a report
appearing during the preparation of this manuscript [35].
Monocytes are known to be exceptionally plastic in phe-
notype and function, with a great capacity to adapt quickly to
environmental stimuli [23, 36]. Monocyte HLA-DR, CD11c,
CD40 and CD14 are typically present on all monocytes, and
they were selected because a high expression level has been
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our knowledge, only for one of them, i.e. HLA-DR, has low
expression been associated with immunosuppression [37].
However, we observe a clearly reduced cell surface intensity
of HLA-DR, CD11c, and CD14 in comparison to the healthy
control group in primarily septic shock and Gram-positive
patients, in conjunction with a high level of immunosuppres-
sive CD163+ monocytes. This also correlated to an increased
proportion of the immunosuppressive HLA-DR−/low (%)
monocyte population, in the septic shock and Gram-positive
patient groups. In general, it was interesting to note that, in
sharp contrast to the Gram-positive patient group, patients
with Gram-negative sepsis had a trend towards a pro-
inflammatory activated monocyte pattern. Whether this dif-
ference is due to different immune response patterns being
elicited by the various pathogens or is due to the clinical
severity of the disease is worth discussing. Importantly how-
ever, monocyte CD40 expression showed a marked variation
in all cases and sepsis groups, including shock, thus indicating
an active CD40:CD40L immune activation also in patients
with a typical immunosuppressive monocyte phenotype re-
garding HLA-DR, CD11c and CD14.
T cells are not counted as antigen-presenting cells, and,
thus, are considered to lack HLA-DR; nevertheless, it is
common knowledge that, upon activation, both CD4+ and
CD8+ T cells express this molecule on their surface [22, 38].
We considered HLA-DR to be a suitable T cell activation
marker for the present study, not only because of its strong
fluorescence intensity, but also with regard to its in vivo
expression (whereas, in our experience, the upregulation of
e.g. CD25, i.e. the IL2R, can only rarely be documented in
patients while being easily detected in T cells activated
ex vivo) and to its kinetics, peaking relatively late (whereas
e.g. CD69 appears already 2 h after stimulation). On average,
none of the sepsis patient subgroups analysed had significant-
ly altered proportions of activated T cells; however, especially
in the shock group, there were cases with marked elevation or
reduction, respectively, of activated T cells. Interestingly, the
alternative activation marker for T cells, CD40 [16, 39], was
increased in all sepsis groups, suggesting further studies on
this population in sepsis patients. Also, in the context of Tregs,
this indicates that, although sepsis is a disease that, at the time
points in this study (1–4 days after onset), would be expected
to affect cells of the innate immune system primarily, we do
actually see an activation of adaptive immunity.
Our observation of altered in vivo concentrations of cyto-
kines in sepsis patients is in agreement with previous data
[35], and provides evidence that our cellular results reflect
functional derangements. Patient serum cytokine levels with































































































Fig. 6 Plasma cytokine concentrations. The box plots represent the
variations in actual serum concentrations of IL-6, IL-18 and TIMP-1 in
patient serum as compared to healthy controls (HC). *p<0.05, **p<0.01,
***p<0.001
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respect to the type of pathogen might be worth analysing in
more detail in the future, as would IL-10 levels in general.
There are certainly additional factors to be considered when
the relevance for the clinical situation of our findings are
assessed, for example, whether a cellular change in the blood
compartment results from the recruitment of cells from major
reservoirs such as spleen or from an altered cellular state or
even selective apoptosis of certain populations. A recent post-
mortem study on sepsis suggests that blood findings can
mirror tissue status, because flow cytometric analysis of both
spleen and lung cells showed the expansion of suppressor cell
populations [12]. A critical issue is which immunosuppressive
characteristics indicate that the patient is in a net state of
immunosuppression conferring increased susceptibility to mi-
croorganisms, and, thus, should be treated accordingly.
Whether an isolated finding of an increase in an immunosup-
pressive monocyte marker such as HLA-DR, CD163 or
programmed cell death protein 1 (PD-1) [12, 40, 41] merit
immunoactivating treatment is worth debating. The principal
issue is: what amount of measurable phenotypic or functional
cellular depression is needed in order for a clinically relevant
immunodeficiency to occur. In conclusion, our findings of a
pronounced inter-individual variation in the analysed mono-
cyte and lymphocyte markers form a strong argument that,
when immunomodulatory treatment is considered in a sepsis
patient, it should be personalised and guided by a detailed
immune status assessment.
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